Trial Profile
A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary) ; Stiripentol; Valproate; Valproate
- Indications Myoclonic epilepsies
- Focus Pharmacokinetics
- Sponsors Jazz Pharmaceuticals Inc
- 30 Apr 2020 Results evaluating the effect of cannabidiol on steady-state pharmacokinetics of stiripentol or valproate in patients with epilepsy, and the safety and tolerability of cannabidiol, published in the CNS Drugs
- 23 Sep 2019 Status changed from recruiting to completed.
- 26 Jun 2019 This trial is completed in Sweden (End Date: 27 May 2019), according to European Clinical Trials Database record.